Group 1: Company Transactions - CureVac N.V. is proposed to be sold to BioNTech SE, with each CureVac share exchanged for approximately $5.46 in BioNTech ADSs, resulting in CureVac shareholders owning between 4% and 6% of BioNTech post-transaction [1] - Know Labs, Inc. is set to be sold to Goldeneye 1995 LLC, with details on shareholder rights available [2] - Volato Group, Inc. will merge with M2i Global, Inc., with current Volato shareholders expected to own approximately 10% of the combined entity after the merger [2] - Heliogen, Inc. is proposed to be sold to Zeo Energy Corp., with Heliogen's securityholders receiving shares valued at approximately $10 million based on a price of $1.5859 per share, subject to adjustments [3] Group 2: Legal Rights and Options - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the aforementioned transactions, and may seek increased consideration for shareholders [4] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [5]

Group 1: CureVac N.V. Acquisition - CureVac will be acquired by BioNTech SE, with each CureVac share exchanged for approximately $5.46 in BioNTech ADSs, leading to an implied aggregate equity value of about $1.25 billion [2] - Upon completion of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech [2] - The investigation focuses on whether the CureVac Board breached its fiduciary duties by failing to conduct a fair process and whether the consideration provides fair value to shareholders [2] Group 2: Know Labs, Inc. Acquisition - Know Labs will be acquired by Goldeneye 1995 LLC, with the purchase price determined by dividing the sum of 1,000 Bitcoin and a cash amount for debt retirement and working capital by the per share price of $0.335 [4] - The investigation examines whether the Know Labs Board breached its fiduciary duties by not conducting a fair process and whether the deal offers fair value to shareholders [4] Group 3: Volato Group, Inc. Merger - Volato Group will merge with M2i Global, with M2i Global expected to own approximately 90% of the total shares of Volato post-merger [6] - The investigation is centered on whether the Volato Group Board breached its fiduciary duties by failing to conduct a fair process and the potential dilution of shareholders in the combined company [6] Group 4: Heliogen, Inc. Acquisition - Heliogen will be acquired by Zeo Energy Corp, with securityholders receiving shares valued at approximately $10 million based on a price of $1.5859 per share, subject to adjustments based on net cash at closing [8] - The investigation looks into whether the Heliogen Board breached its fiduciary duties by not conducting a fair process and whether the consideration provides fair value to shareholders [8]

Core Insights - The Chinese innovative pharmaceutical industry is experiencing a surge in License-out transactions, with total transaction amounts reaching $45.5 billion in the first five months of 2025, compared to $51.9 billion for the entire year of 2024 [1] - A notable event is the agreement between 3SBio and Pfizer on May 20, 2025, for exclusive global development rights worth over $6 billion, setting a record for upfront payments in China at $1.25 billion [1] - The trend indicates increasing recognition of Chinese companies' R&D capabilities by multinational pharmaceutical firms [1] Group 1: Market Trends - The innovative drug sector is entering a recovery phase, with significant business development (BD) transactions occurring, leading to rising stock prices for related companies [3] - The market is witnessing a return to reasonable valuations for many innovative drug companies, although some still have a way to go [3] - The trend of License-out transactions and NewCo models is seen as beneficial for innovative drug companies to secure funding for further R&D [2] Group 2: Investment Opportunities - Companies like Chengyi Biotech and Yiming Biotech have achieved notable BD transactions, positively impacting their product pipelines and capital market progress [3] - Chengyi Biotech's collaboration with AstraZeneca is valued at $2.01 billion, including an upfront payment of $185 million [3] - Yiming Biotech has secured multiple partnerships, including a $1.7 billion deal with BioNTech and a strategic collaboration with BeiGene [4] Group 3: Future Outlook - The number of Chinese pharmaceutical companies may consolidate from nearly 5,000 to around 300-500, driven by mergers and acquisitions [6] - The focus on product differentiation and technological leadership is crucial for investment decisions in innovative drug companies [6][7] - The investment landscape is becoming more rational, with a clear distinction between high-quality companies and those with similar pipelines struggling to attract capital [8]

智通财经APP获悉，周四，三大指数上涨，美国通胀似乎正在向美联储2%的目标迈进，而劳动力数据 显示失业率可能会上升。5月PPI小幅上升0.1%，申请失业救济人数仍保持在24.8万人的高位。这些因素 加在一起，增强了人们对美联储可能在今秋初降息的预期。美国商务部宣布将自6月23日起对多种钢制 家用电器加征关税，包括洗碗机、洗衣机和冰箱等"钢铁衍生产品"。据悉，对大多数国家设定50%的关 税将影响这些钢铁制品的进口，可能导致消费价格上涨，行业利益相关者正在密切关注事态发展。 【美股】截至收盘，道指涨101.85点，涨幅为0.24%，报42967.62点；纳指涨46.61点，涨幅为0.24%，报 19662.48点；标普500指数涨23.02点，涨幅为0.38%，报6045.26点。英伟达(NVDA.US)涨1.5%，特斯拉 (TSLA.US)跌超2%，波音(BA.US)跌4.7%。纳斯达克中国金龙指数收跌0.44%，小鹏汽车(XPEV.US)跌近 6%。 【欧股】德国DAX30指数跌202.78点，跌幅0.85%，报23773.33点；英国富时100指数涨20.13点，涨幅 0.23%，报8884.48点；法国C ...

Group 1 - CureVac NV's stock surged 32.2% to $5.37 following the announcement of BioNTech's acquisition of the company in an all-stock deal valued at $1.25 billion [1] - The merger is pending review by the German Economy Ministry, and CureVac's stock is trading at 52-week highs, breaking through the $5 resistance level [1] - Since the beginning of 2025, CureVac's equity has increased by 63.5% [1] Group 2 - CureVac's options market is experiencing significant activity, with trading volume reaching 45 times the average daily volume, particularly in the June 6 call options [2] - Short interest in CureVac has decreased by 14.1% over the past two weeks, although it still represents 4.4% of the stock's available float [2] - It would take over six days for short sellers to cover their positions based on CureVac's average trading pace [2]

Core Viewpoint - BioNTech SE has agreed to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion, aiming to enhance its capabilities in mRNA-based cancer immunotherapy [1][3]. Group 1: Transaction Details - Shareholders of CureVac can exchange their shares for about $5.46 in BioNTech ADSs, with the equity value of the deal being around $1.25 billion [1]. - The transaction includes a collar mechanism affecting the exchange ratio based on the 10-day volume weighted average price (VWAP) of BioNTech ADSs, with specific ratios set for prices above $126.55 and below $84.37 [2]. - Upon closing, CureVac shareholders are expected to own between 4% and 6% of BioNTech [2]. Group 2: Strategic Implications - The acquisition is part of BioNTech's oncology strategy, which includes mRNA-based cancer immunotherapy candidates and a bispecific antibody candidate, BNT327 [4]. - BioNTech plans to integrate CureVac's research and manufacturing site in Tübingen, enhancing its research, development, and manufacturing capabilities [4]. Group 3: Financial Context - BioNTech had €15.9 billion in cash, cash equivalents, and security investments as of March 31 [5]. - The transaction was unanimously approved by both companies' management and supervisory boards and is expected to close in 2025 [5]. Group 4: Related Agreements - BioNTech has a co-development and co-commercialization agreement with Bristol Myers Squibb, which includes an upfront payment of $1.5 billion and potential additional payments totaling up to $7.6 billion [6].

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced and qualified news journalists who produce independent content [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is recognized for its forward-looking approach and enthusiastic adoption of technology to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all content is edited and authored by humans [5]

美国5月通胀依然温和，表明当前的关税尚未明显推高消费价格。市场普遍预计，美联储将在下周的会议上维持利率不变，等待观察特朗 普政策对经济的影响。 股市方面，PPI和就业数据公布后，盘前美股期货跌幅收窄。美股盘初，三大股指小幅下跌，道指跌0.36%，标普500指数跌0.2%，纳指 跌0.2%。 | 트 道琼斯指数 | 42,668.05 | 42,737.36 | 42,606.42 | -197.72 | -0.46% | | --- | --- | --- | --- | --- | --- | | 트 标普500指数 | 6.017.59 | 6,017.75 | 6,003.88 | -4.71 | -0.08% | | 트 纳斯达克综合指数 | 19,591.14 | 19,599.09 | 19,553.56 | -24.74 | -0.13% | 标普500指数自4月低点反弹逾20%之后，股市交易活跃度开始显示出疲态。 中概股多数下跌，哔哩哔哩跌约1%。科技股多数下跌，特斯拉跌约1%。 美国就业市场、通胀均降温。美国上周首次申请高于预期，续请人数飙升至2021年底来最高，美国5月PPI环比温和上涨0 ...

Core Insights - Bristol Myers (BMY) announced that the late-stage study on Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA) met its primary endpoint, indicating significant efficacy [1][4] - Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor, representing a new class of small molecules and is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases [1][4] - The drug is already approved in numerous countries for the treatment of adults with moderate-to-severe plaque psoriasis [2] Study Results - The phase III POETYK PsA-1 study involved 670 patients and showed a significantly greater proportion of patients treated with Sotyktu achieving ACR20 response compared to placebo at week 16 [4] - Key secondary endpoints met include Psoriasis Area and Severity Index (PASI) 75 response, Health Assessment Questionnaire-Disability Index (HAQ-DI) score, 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) score, and Minimal Disease Activity (MDA) response [5] - The late-stage PsA program includes two phase III trials, POETYK PsA-1 and POETYK PsA-2, with the latter enrolling approximately 730 patients [6] Licensing and Strategic Moves - BMY's subsidiary RayzeBio entered into a $1.35 billion licensing deal with Philochem for the prostate cancer therapy OncoACP3, which includes a $350 million upfront payment and potential milestones of $1 billion [9][10] - BMY is looking to expand its portfolio and pipeline due to generic competition faced by legacy drugs, with a potential label expansion of Sotyktu to broaden its target patient population [11] - A strategic collaboration agreement was announced with BioNTech for the co-development and co-commercialization of the investigational bispecific antibody BNT327 [12] Market Performance - Shares of Bristol Myers have declined by 15.9% over the past three months, while the industry has seen a decline of 5.3% [2] - BMY has experienced pipeline setbacks recently, negatively impacting its share price [13]

Group 1 - The Dow Jones Industrial Average fell by 0.41%, the S&P 500 decreased by 0.19%, and the Nasdaq dropped by 0.18% [1] - Oracle's stock rose over 7% as the CEO indicated that cloud infrastructure revenue is expected to increase by more than 70% in the new fiscal year [1] - Boeing's stock declined by over 5% following the first incident involving its 787 aircraft [1] - Biotech company CureVac's stock surged over 30% after reports emerged that BioNTech plans to acquire CureVac for $1.25 billion [1]